Literature DB >> 12967577

Oral ketamine in paediatric non-convulsive status epilepticus.

L D Mewasingh1, T Sékhara, A Aeby, F J C Christiaens, B Dan.   

Abstract

In children, non-convulsive status epilepticus (NCSE) is rare and difficult to treat. Response to steroids and GABAergic medication is variable and often decreases with increasing duration of NCSE. We present our experience with oral ketamine, an NMDA-receptor antagonist, administered to five children with severe epilepsy (Lennox-Gastaut Syndrome, myoclonic-astatic epilepsy, progressive myoclonic epilepsy and Pseudo-Lennox Syndrome) during an episode of NCSE. Resolution of NCSE was documented in all cases clinically and electroencephalographically within 24-48 hours of starting ketamine. No significant side effects were noted.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12967577     DOI: 10.1016/s1059-1311(03)00028-1

Source DB:  PubMed          Journal:  Seizure        ISSN: 1059-1311            Impact factor:   3.184


  15 in total

1.  Treatment of refractory status epilepticus in childhood.

Authors:  John M Schreiber; William D Gaillard
Journal:  Curr Neurol Neurosci Rep       Date:  2011-04       Impact factor: 5.081

2.  Ketamine for Refractory Status Epilepticus: A Systematic Review.

Authors:  Anna Rosati; Salvatore De Masi; Renzo Guerrini
Journal:  CNS Drugs       Date:  2018-11       Impact factor: 5.749

3.  Early ketamine to treat refractory status epilepticus.

Authors:  Andreas H Kramer
Journal:  Neurocrit Care       Date:  2012-04       Impact factor: 3.210

4.  Enhanced AMPA receptor-mediated neurotransmission on CA1 pyramidal neurons during status epilepticus.

Authors:  Suchitra Joshi; Karthik Rajasekaran; Huayu Sun; John Williamson; Jaideep Kapur
Journal:  Neurobiol Dis       Date:  2017-04-02       Impact factor: 5.996

5.  Guidelines for the evaluation and management of status epilepticus.

Authors:  Gretchen M Brophy; Rodney Bell; Jan Claassen; Brian Alldredge; Thomas P Bleck; Tracy Glauser; Suzette M Laroche; James J Riviello; Lori Shutter; Michael R Sperling; David M Treiman; Paul M Vespa
Journal:  Neurocrit Care       Date:  2012-08       Impact factor: 3.210

6.  Rapid surface accumulation of NMDA receptors increases glutamatergic excitation during status epilepticus.

Authors:  David E Naylor; Hantao Liu; Jerome Niquet; Claude G Wasterlain
Journal:  Neurobiol Dis       Date:  2013-01-08       Impact factor: 5.996

7.  A comparison of three NMDA receptor antagonists in the treatment of prolonged status epilepticus.

Authors:  Weiwei Yen; John Williamson; Edward H Bertram; Jaideep Kapur
Journal:  Epilepsy Res       Date:  2004-03       Impact factor: 3.045

Review 8.  Literature review, case report, and expert discussion of prolonged refractory status epilepticus.

Authors:  T K Robakis; L J Hirsch
Journal:  Neurocrit Care       Date:  2006       Impact factor: 3.210

Review 9.  NMDA antagonists for refractory seizures.

Authors:  F A Zeiler; J Teitelbaum; L M Gillman; M West
Journal:  Neurocrit Care       Date:  2014-06       Impact factor: 3.210

10.  A combination of ketamine and diazepam synergistically controls refractory status epilepticus induced by cholinergic stimulation.

Authors:  Brandon S Martin; Jaideep Kapur
Journal:  Epilepsia       Date:  2007-10-15       Impact factor: 5.864

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.